Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2002-7-10
pubmed:abstractText
Activation of calpain results in the breakdown of alpha II spectrin (alpha-fodrin), a neuronal cytoskeleton protein, which has previously been detected in various in vitro and in vivo neuronal injury models. In this study, a 150 kDa spectrin breakdown product (SBDP150) was found to be released into the cell-conditioned media from SH-SY5Y cells treated with the calcium channel opener maitotoxin (MTX). SBDP150 release can be readily quantified on immunoblot using an SBDP150-specific polyclonal antibody. Increase of SBDP150 also correlated with cell death in a time-dependent manner. MDL28170, a selective calpain inhibitor, was the only protease inhibitor tested that significantly reduced MTX-induced SBDP150 release. The cell-conditioned media of cerebellar granule neurons challenged with excitotoxins (NMDA and kainate) also exhibited a significant increase of SBDP150 that was attenuated by pretreatment with an NMDA receptor antagonist, R(-)-3-(2-carbopiperazine-4-yl)-propyl-1-phosphonic acid (CPP), and MDL28170. In addition, hypoxic/hypoglycemic challenge of cerebrocortical cultures also resulted in SBDP150 liberation into the media. These results support the theory that an antibody-based detection of SBDP150 in the cell-conditioned media can be utilized to quantify injury to neural cells. Furthermore, SBDP150 may potentially be used as a surrogate biomarker for acute neuronal injury in clinical settings.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1431-6730
pubmed:author
pubmed:issnType
Print
pubmed:volume
383
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
785-91
pubmed:dateRevised
2006-5-19
pubmed:meshHeading
pubmed-meshheading:12108543-Analysis of Variance, pubmed-meshheading:12108543-Animals, pubmed-meshheading:12108543-Anoxia, pubmed-meshheading:12108543-Blotting, Western, pubmed-meshheading:12108543-Calpain, pubmed-meshheading:12108543-Cell Death, pubmed-meshheading:12108543-Cells, Cultured, pubmed-meshheading:12108543-Cerebellum, pubmed-meshheading:12108543-Cerebral Cortex, pubmed-meshheading:12108543-Dipeptides, pubmed-meshheading:12108543-Dose-Response Relationship, Drug, pubmed-meshheading:12108543-Glucose, pubmed-meshheading:12108543-Humans, pubmed-meshheading:12108543-Marine Toxins, pubmed-meshheading:12108543-Nerve Tissue Proteins, pubmed-meshheading:12108543-Neuroblastoma, pubmed-meshheading:12108543-Neurons, pubmed-meshheading:12108543-Neurotoxins, pubmed-meshheading:12108543-Oxocins, pubmed-meshheading:12108543-Rats, pubmed-meshheading:12108543-Rats, Sprague-Dawley, pubmed-meshheading:12108543-Spectrin, pubmed-meshheading:12108543-Time Factors
pubmed:year
2002
pubmed:articleTitle
Selective release of calpain produced alphalI-spectrin (alpha-fodrin) breakdown products by acute neuronal cell death.
pubmed:affiliation
Department of Neuroscience Therapeutics, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA.
pubmed:publicationType
Journal Article